Trial Profile
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 5-453 and Metabolites Following a Single-dose Oral Administration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2017
Price :
$35
*
At a glance
- Drugs Etamicastat (Primary)
- Indications Heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors Bial
- 03 Dec 2015 New trial record